This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Beam Therapeutics' Phase 1/2 results for BEAM-302 for patients with AATD.
Ticker(s): BEAMWho's the expert?
Institution: Weill Cornell Medical College
- Professor and chairman at the department of Genetic Medicine at Weill Cornell Medical College, as well as the Bruce Webster Professor of Internal Medicine
- First person to demonstrate that a recombinant adenovirus could be used to effectively transfer genes in vivo
- Much of his research focuses on the pathogenesis and treatment of inflammatory lung diseases
- Responsible for numerous biomedical patents and is the founder of several biotechnology companies focusing on gene therapies
Interview GoalThis conversation will focus on the treatment landscape and potential use of BEAM-302 for patients with AATD.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
